ES2092579T3 - Agentes homobifuncionales para el acoplamiento de enzimas y similares a anticuerpos y similares. - Google Patents

Agentes homobifuncionales para el acoplamiento de enzimas y similares a anticuerpos y similares.

Info

Publication number
ES2092579T3
ES2092579T3 ES91920049T ES91920049T ES2092579T3 ES 2092579 T3 ES2092579 T3 ES 2092579T3 ES 91920049 T ES91920049 T ES 91920049T ES 91920049 T ES91920049 T ES 91920049T ES 2092579 T3 ES2092579 T3 ES 2092579T3
Authority
ES
Spain
Prior art keywords
intrinsic factor
group
disclosed
solution
purified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91920049T
Other languages
English (en)
Inventor
Christopher Bieniarz
Christopher Welch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Application granted granted Critical
Publication of ES2092579T3 publication Critical patent/ES2092579T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/06—Enzymes or microbial cells immobilised on or in an organic carrier attached to the carrier via a bridging agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REVELO UN AGENTE ACOPLADOR UTIL PARA REALIZAR ENSAYOS INMUNOLOGICOS, ESPECIALMENTE EN ENSAYOS DE B12. EL AGENTE ACOPLADOR TIENE LA FORMULA (I), DONDE Z Y Z'' PUEDEN SER IGUALES O DIFERENTES Y CADA UNO REPRESENTA A H2NHN,ICH2, (A) O (B); K, M Y N SON ENTEROS ENTRE 1 Y 10, X PUEDE SER UN GRUPO ALQUILENICO, CICLOALQUILENICO O ALQUILOCICLOALQUILENICO, UN GRUPO AROMATICO BIVALENTE O AMINOALQUILENICO, R Y R'' PUEDEN SER IGUALES O DIFERENTES, Y CADA UNO REPRESENTA A UN GRUPO AMINOALQUILENICO SUSTITUIDO O NO SUSTITUIDO CON ENTRE 1 Y 10 ATOMOS DE CARBONO O UN GRUPO CICLOALQUILENICO O ALQUILOCICLOALQUILENICO CON ENTRE 5 Y 20 ATOMOS DE CARBONO. Z Y Z'' SON IGUALES, EXCEPTO CUANDO JUNTOS FORMAN (C), ENTONCES PUEDEN SER IGUALES O DIFERENTES. SE REVELO UN METODO PARA LA PURIFICACION DE UNA SOLUCION ACUOSA DE FACTOR INTRINSECO QUE CONTIENE PROTEINA R. EL METODO DE PURIFICACION IMPLICA QUE SE AÑADE UNA CANTITAD SUFICIENTE DE COBINAMIDA PARA QUE SE LIGUE SUSTANCIALMENTE A TODA LA PROTEINA R DE LA SOLUCION YDE UNA CANTIDAD SUFICIENTE DE UNA RESINA AFIN AL FACTOR INTRINSECO PARA LIGARSE A ESTE EN LA SOLUCION, QUE SE LAVE LA COBINAMIDA LIGADA Y LA PROTEINA R DE LA RESINA, QUE SE ELUYA EL FACTOR INTRINSECO DE LA RESINA Y QUE SE DIALICE EL FACTOR INTRINSECO ELUIDO. EL FACTOR INTRINSECO PUEDE CONTENER MENOS DE 0,004 POR CIENTO DE REACTIVIDAD RECIPROCA CON LAS COBINAMIDAS Y AL MENOS EL 95 POR CIENTO DE LAS PROTEINAS DEL MATERIAL PURIFICADO PUEDEN LIGAR COBALAMINAS. TAMBIEN SE REVELO UNA UNION EN LA QUE MICROPARTICULAS Y EL FACTOR INTRINSECO ESTAN CONJUGADOS MEDIANTE UNA PARTE DE LOS AGENTES ACOPLADORES PRECEDENTES, AL IGUAL QUE UN SISTEMA PARA REALIZAR UN ENSAYO PARA COBALAMINAS QUE INCLUYE LA UNION CONJUGADA DE MICROPARTICULAS Y DEL FACTOR INTRINSECO PURIFICADO. TAMBIEN SE REVELO UN METODO PARA REALIZAR UN ENSAYO PARA COBALAMINAS, CUYO METODO IMPLICA EL EMPLEO DE LA UNION CONJUGADA DE MICROPARTICULAS Y EL FACTOR INTRINSECO.
ES91920049T 1990-10-22 1991-10-18 Agentes homobifuncionales para el acoplamiento de enzimas y similares a anticuerpos y similares. Expired - Lifetime ES2092579T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60079590A 1990-10-22 1990-10-22

Publications (1)

Publication Number Publication Date
ES2092579T3 true ES2092579T3 (es) 1996-12-01

Family

ID=24405079

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91920049T Expired - Lifetime ES2092579T3 (es) 1990-10-22 1991-10-18 Agentes homobifuncionales para el acoplamiento de enzimas y similares a anticuerpos y similares.

Country Status (12)

Country Link
US (1) US5380873A (es)
EP (1) EP0555336B1 (es)
JP (2) JP3360174B2 (es)
KR (1) KR930702683A (es)
AT (1) ATE140795T1 (es)
AU (1) AU657284B2 (es)
CA (1) CA2094397C (es)
DE (1) DE69121108T2 (es)
DK (1) DK0555336T3 (es)
ES (1) ES2092579T3 (es)
GR (1) GR3021097T3 (es)
WO (1) WO1992007268A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08507686A (ja) * 1993-03-09 1996-08-20 アボツト・ラボラトリーズ 遺伝子操作酵素及びそれらの診断アッセイ用結合体
US5548064A (en) * 1993-05-24 1996-08-20 Biotech Australia Pty Limited Vitamin B12 conjugates with EPO, analogues thereof and pharmaceutical compositions
US6306665B1 (en) * 1999-10-13 2001-10-23 A-Fem Medical Corporation Covalent bonding of molecules to an activated solid phase material
US7193065B2 (en) * 2001-07-13 2007-03-20 Roche Diagnostics Operations, Inc. Protease inhibitor conjugates and antibodies useful in immunoassay
EP3144675A1 (en) 2005-04-28 2017-03-22 Ventana Medical Systems, Inc. Enzymes conjugated to antibodies via a peg heterobifuctional linker
JP4793714B2 (ja) * 2005-05-19 2011-10-12 独立行政法人産業技術総合研究所 新規クロスリンカー化合物
US20070117153A1 (en) 2005-11-23 2007-05-24 Christopher Bieniarz Molecular conjugate
WO2008136769A1 (en) * 2007-05-03 2008-11-13 Nanyang Technological University Online contaminant detection and removal system

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU626809B2 (en) * 1987-10-30 1992-08-13 Abbott Laboratories Heterobifunctional coupling agents
US5066490A (en) * 1988-06-01 1991-11-19 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Protein crosslinking reagents cleavable within acidified intracellular vesicles
US5104815A (en) * 1988-10-11 1992-04-14 Abbott Laboratories Assay for cobalamins
ATE154135T1 (de) * 1989-03-10 1997-06-15 Hoffmann La Roche Reagenzien zum nachweis von drogen

Also Published As

Publication number Publication date
DE69121108T2 (de) 1997-02-27
DE69121108D1 (de) 1996-08-29
JP3488670B2 (ja) 2004-01-19
JP3360174B2 (ja) 2002-12-24
AU8905991A (en) 1992-05-20
JPH06502411A (ja) 1994-03-17
US5380873A (en) 1995-01-10
EP0555336B1 (en) 1996-07-24
DK0555336T3 (da) 1996-11-25
EP0555336A1 (en) 1993-08-18
KR930702683A (ko) 1993-09-09
WO1992007268A1 (en) 1992-04-30
CA2094397C (en) 2005-10-04
EP0555336A4 (en) 1994-10-12
GR3021097T3 (en) 1996-12-31
ATE140795T1 (de) 1996-08-15
JP2000229926A (ja) 2000-08-22
AU657284B2 (en) 1995-03-09
CA2094397A1 (en) 1992-04-23

Similar Documents

Publication Publication Date Title
DE3067935D1 (en) Antitumor protein hybrid and process for the preparation thereof
GR3015558T3 (en) Chemically modified protein and production thereof.
ES8700672A1 (es) Un procedimiento para la preparacion de derivados de amino alquilentio-alquilentiofosfonatos.
DE3483869D1 (de) Zusammensetzungen zur bekaempfung von toxaemia.
ATE43847T1 (de) Glykoside, glykoconjugate und verfahren zu ihrer herstellung.
ES2092579T3 (es) Agentes homobifuncionales para el acoplamiento de enzimas y similares a anticuerpos y similares.
ES8506902A1 (es) Un procedimiento para la purificacion de un antigeno.
BR9815493A (pt) Citólise dirigida de células-alvo, agentes e composições que causam citólise, e compostos que podem ser usados para produzir os agentes
EP1242115A4 (en) CHEMICALLY PROGRAMMABLE IMMUNITY
CA2172663A1 (en) Improved reagents for a cannabinoid immunoassay
DE3878804D1 (de) Pigmentzubereitungen, verfahren zu ihrer herstellung und ihre verwendung.
JPS55136235A (en) Antitumor protein complex and its preparation
ATE20597T1 (de) Polymermischungen und diese enthaltende zusammensetzung.
FR2560212B1 (fr) Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps
EP0378203A3 (de) Neue Cobalamin-Säurehydrazide und davon abgeleitete Cobalamin-Konjugate
ATE276274T1 (de) Konjugate von alpha-msh mit einer fettsäure, verfahren zu ihrer herstellung und ihre verwendung als medikament
Amaral et al. Human liver nuclear transcortin its postulated role in glucocorticoid regulation of genetic activity
ES2082132T3 (es) Composicion que contiene al menos dos anticuerpos distintos o fragmentos de ellos.
MY107983A (en) Glass fiber reinforced polyamide composition and the process for manufacturing the same.
ATE69444T1 (de) N-substituierte-n-nitroso-aminoacetonitrile, verfahren zu ihrer herstellung und ihre verwendung.
MIYAZAKI et al. Preparation of antibody (IgG)-ricin A-chain conjugate and its biologic activity
PT684835E (pt) Antagonistas de ligandos para o tratamento do cancro da mama
SE8703453D0 (sv) Preparation innehallande hogmolekylert bakteriellt protein, antikroppspreparation riktad deremot samt preparationernas anvendning
Harmon Purification of antibodies against biotin on lipoic acid-sepharose
DE3468324D1 (en) Specific antibody to the native form of 2'5'-oligonucleotides, the method of preparation and the use as reagents in immunoassays or for binding 2'5'-oligonucleotides in biological systems

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 555336

Country of ref document: ES